Ascenion is pleased to announce the forthcoming BioVaria 2008, presenting “Germany’s next top technologies”, to be held in Munich on 8 May 2008
With presentations by top scientists from all over Germany, the event will showcase about 50 patent-protected technologies that will appeal to companies looking to collaborate at an early stage of commercial development. Topics will cover, among other things, the diagnosis or treatment of cancer, infectious diseases, metabolism, autoimmune and neurodegenerative disorders.
The conference is organised by Ascenion and its partners EMBLEM, National Genome Research Network, Fraunhofer VLS, PROvendis, MediGate GmbH, ipal GmbH and DKFZ.For further information and updates please visit the BioVaria website.
Key features of the event include:
- A host of distinguished speakers and 10-min presentations from top scientists from Public Research Institutions and Universities
- An all-day poster exhibition featuring undiscovered, licensable technologies
- Discussion of scientific details face-to-face with inventors
- Networking with academic scientists and delegates from the Bioscience & Pharmaceutical Industry
Registration fees include access to presentations and poster exhibition, conference booklet, coffee breaks and lunch. Early registration before February 28, 2008 guarantees a discounted fee.
Ascenion GmbH is an IP asset management company focused on the life sciences. Ascenion supports and advises scientists and research institutions with regard to the protection and exploitation of their intellectual property (patents, know-how, materials), and initiates and mediates license agreements between research institutions and industry. Ascenion was founded in 2001 as a 100% subsidiary of the Life-Science Foundation for the Promotion of Science and Research and has since acquired 12 research institutes in the Helmholtz and Leibniz Associations and also the Hanover Medical School as exclusive partners. On behalf of these institutes, Ascenion currently markets around 600 technologies and closes an average of about 60 agreements between research and industry per year. The team has also accompanied numerous spin-offs through their foundation and early growth and Ascenion holds equity in 12 of these companies. Ascenion’s headquarters are in Munich, with further offices in Berlin, Braunschweig, Hamburg, Hanover and Neuherberg. Further information at www.ascenion.de